ערך בספרים למניה: PDS Biotechnology Corporation (PDSB)

PDS Biotechnology's optimization of biochemical supply chains, combined with its authority as a leader in T-cell immunity, establishes a resilient business foundation. The IFRS book value per share reflects this potential, with the metric reaching -0.06. The readiness of laboratory capacities for mass drug production promises further growth in the company's capitalization.

The success of PDS Biotechnology (PDSB) depends on the effectiveness of the Versamune platform and regulatory approvals, rendering its market capitalization sensitive to clinical trial results. The book value per share, calculated as the difference between total assets and liabilities, allows for the tracking of hidden asset impairment risks; therefore, the trend in book value per share serves as an indicator of investor protection against value traps.